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ABSTRACT 
 
Exosomes represent a promising new approach to targeted drug delivery. Current research 
explores the ability of these naturally occurring nanoparticles to transport therapeutic cargo to 
specific tissues of the body and to subsequently enter the cells of those tissues. Human cells act 
as an efficient source of these nano-vesicles. Our project ultimately focuses on the establishment 
of a cell line that produces exosomes tagged with the RD114 protein, which allows for the 
targeting of hematopoietic stem cells. With the ability to deliver therapeutic cargo to these 
specific cells, exosomes can serve as a vehicle for many effective hematopoietic stem cell 
therapies. We ultimately developed two stable cell lines that produced engineered exosomes and 
conducted a series of tests on these nanoparticles. Results from these tests indicate that these 
exosomes are tagged with the desired proteins, opening several possibilities for future research. 
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Chapter 1: Introduction 
 
1.1 Background 
Therapeutic biomolecules have been extensively developed to treat a broad range of conditions 
and diseases. In recent years, the delivery of those therapeutics has become a much greater 
concern. Exosomes are now rising to meet that concern. They are natural nanovesicles derived 
from living cells that can carry proteins on their surfaces and therapeutic biomolecules within 
their lumen [1]. Exosome-mediated therapeutic delivery can, in principle, be applied to many 
biomedical situations and this technique has already been utilized to treat various diseases [1, 2]. 
These nanoparticles can carry surface proteins that allow for targeted delivery of the therapeutic 
cargo to the appropriate cells of the human body [4]. By achieving efficient therapeutic delivery, 
exosomes may enhance the efficiency of these therapeutics in medical applications.  
 
Diseases impacting hematopoietic stem cells (HSCs) present several dilemmas to the medical 
community as it seeks to develop effective treatments. They play a critical role in healthy 
physiological processes and give rise to the blood cell lineages of the body [5]. These lineages 
include the megakaryocytes and platelets that facilitate blood clotting processes, erythrocytes 
that transport oxygen from the lungs to peripheral tissues, and cells of the innate and acquired 
immune system [6]. HSCs, like other cells in the body, are susceptible to mutations. These 
mutations can eventually give rise to diseases that affect the cells of the blood. In response to 
these diseases, a few treatment approaches have been developed. In the instance of leukemia, a 
cancer of the blood that hinders the body’s ability to fight off infections, chemotherapy or 
radiation can be applied [7]. Transplantation of healthy HSCs can also be performed to provide a 
patient with a repertoire of HSCs for basic physiological functions. Unfortunately, HSCs taken 
from allogeneic donors can present a risk of immunologic complications [8]. To circumvent 
these challenges, the most practical approach is to examine the treatment of the diseased HSCs in 
the body, possibly through gene therapy. In order for these therapies to be practical and effective, 
however, the mechanism of drug delivery must be considered. 
 
1.2 Review of the Field 
Many delivery systems have been examined as novel drug therapies have been developed. 
Effective drug delivery systems are needed to overcome key barriers that drugs face within the 
body. Drugs often demonstrate poor solubility, cause unintentional tissue damage, and decrease 
in activity over time. Additionally, research has been conducted to address the ongoing need of 
direct drug delivery to the targeted tissues and cells. Such targeted delivery ultimately reduces 
the negative impact of the drug on surrounding tissues while increasing the local concentration of 
the drug within the targeted tissues. In recent years, nanoparticle drug delivery technology has 
come into focus as a potential solution. Various forms of nanotechnology exist, and many of 
them have effectively addressed some of these barriers. 
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Liposomes are nanosized unilamellar phospholipid bilayer vesicles with a central cavity that can 
carry therapeutic cargo within the body [9]. They have been shown to maintain stability as they 
circulate through the body, and research has focused on ways to induce the release of the cargo 
from the liposome through ultrasound, heat, and light stimulation [10]. Also, because they are 
composed of biomolecules, they are naturally inert and induce minimal immune response from 
the body. These nanovesicles encounter a major limitation, however, in their inability to 
effectively target specific cell types. Because they lack surface biomolecules capable of 
governing specific interactions within the body, these nanoparticles cannot effectively 
distinguish between different tissue types.  
 
Gold nanoparticles (AuNPs) are another candidate for drug delivery. They are capable of 
transporting drugs that ordinarily exhibit low solubility, poor pharmacokinetics, and 
susceptibility to enzyme degradation [11]. The surfaces of AuNPs can also be functionalized 
with ligands that allow them to target specific cells and tissues within the body. Further, the size 
of AuNPs present an important advantage. Because AuNPs are roughly equivalent in size to the 
targeted cells, they are able to bind to target cells at multiple receptor sites, thus enhancing their 
uptake into the targeted cells [12]. ​Some studies, however, have called into question the ability of 
AuNPs to induce toxic side effects through natural immune response mechanisms [13]. 
Ultimately, these studies have generated relatively inconsistent results that make the use of 
AuNP drug delivery treatments potentially problematic. 
 
Polymeric nanoparticles are yet another potential mode of drug delivery. These nanoparticles are 
composed of macromolecules that carry an active therapeutic agent. These macromolecular 
structures gradually dissolve over time and release the therapeutic agent to the surrounding cells 
and tissue. This method of release can allow for sustained delivery of the drug to a targeted 
region. These nanoparticles are also relatively easy to synthesize, biocompatible, and 
biodegradable [​14]​. Unfortunately, they also present obstacles of their own. They are not able to 
effectively targeting specific cells and they tend to agglomerate within solution, thus hampering 
their capability for targeted drug delivery. 
 
1.3 Critique of Current Technology  
The major limitation of using liposomes for drug delivery is their lack of targeting ability. 
Liposomes cannot be manufactured with transmembrane proteins that span the lipid bilayer to 
direct the nanoparticle to a desired tissue. Instead, they can only capture biological material 
within their aqueous compartments. This captured material is incapable of directing the actual 
delivery of these nanoparticles to the proper cell types in the body. Gold nanoparticles show a 
variety of promising features, but they are not naturally produced. This ultimately raises a 
concern that they may demonstrate toxic effects ​in vivo​. For polymeric nanoparticles, similarly to 
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liposomes, they do not deliver drugs to specific cells, but rather to a targeted region where their 
therapeutics are then released. In this scenario, it becomes difficult to predict the unintended 
effects that the released drug may impose on surrounding tissues. 
 
Having examined the existing nanotechnologies that are currently employed for drug delivery 
applications, there is a clear need for a practical drug delivery system that meets a complete set 
of criteria. Exosomes are appealing candidates to meet these standards.  
 
1.4 Project Goal  
This project is dedicated to the development and execution of a robust and reliable gene 
integration protocol that will allow for efficient production of targeted nanoparticles from a 
stable HEK293 cell line. To overcome the disadvantages of other nanoparticles, we will explore 
exosomes for our project. Exosomes are naturally derived, living nanoparticles that allow for 
therapeutic protein transport ​in vivo​. Due to their origination from living systems, exosomes are 
biocompatible and stable. They can also permeate biological barriers with low toxicity and 
immunogenicity [15]. They can carry proteins in both their aqueous interior compartment as well 
as in their lipid membrane. Because of their ability to carry transmembrane proteins, these 30 to 
100 nm vesicles can be used to carry proteins that target specific tissues to treat various diseases.  
 
The first step in approaching this project will be to use previously established protocols to 
develop and maintain a stable HEK293 cell line. This cell line will be used to run various 
experiments over the course of this project. The next milestone of the project will be the cell line 
transfection. To determine if our transfection created a stable cell line with our vector, we will 
monitor the cells for 40 days and confirm continued expression of the vector in the cells with a 
fluorescent protein. Luminescent proteins will also help us quantify the successful integration of 
the vector through imaging and luciferase assays. Through imaging, we will be able to observe 
the location of our protein within the cell. We will confirm that the proteins are on the exosomal 
membranes through exosome harvesting and analysis. This leads to our last step of experiments 
and our expected outcome. We will do uptake experiments with our exosomes and a cell line to 
show that our exosomes can deliver therapeutics to these cells. Then, we will produce a 
conclusive protocol with our proven methods that future students can use to repeat our process. 
 
1.5 Backup Plan  
The main concern with this project is the 2-3 month timeline that is required to verify the 
stability of our generated cell lines following their transfection. If the vectors are not successfully 
integrated into the cell line genome after the first or second attempted transfection, there will not 
be enough time to complete this process. Our alternative plan is to execute a transduction 
procedure using a lentivirus gene delivery process. This method of integration can be performed 
to integrate the viral vectors into the HEK293 cells over a shorter timeline. Transduction only 
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requires 1-2 weeks to confirm the integration of the target gene and the creation of a stable cell 
line. This will allow us to reach our project goal in a shorter amount of time if we run into 
complications so that we can still complete our project.  
 
1.6 Significance  
This method of exosome production can be used to develop therapeutic carriers that are designed 
to treat a variety of diseases within a broad range of cell types through targeted drug delivery. 
Exosome-mediated drug delivery also presents unique advantages over other drug delivery 
methods. Because these nanovesicles can be derived from human cells, they have ultimately 
demonstrated a lower potential to induce an immune response from the body [16]. Exosome 
technology has already been explored as a potential approach to the treatment of a broad range of 
diseases. The outcomes of this project could simplify the process by which these targeted 
nanoparticles are produced and consequently make the technology more accessible for clinical 
applications around the world. 
 
 
1.7 Team and Management 
1.7.1 Team Members 
Table 1. ​Project Members 
Member Degree Email 
Anja Beard Bioengineering - 
Biomolecular Track 
abeard@scu.edu 
Zach Ehlinger Bioengineering - 
Biomolecular Track 
zehlinger@scu.edu 
 
Advisor: 
Dr. Biao (Bill) Lu 
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1.7.2 Project Budget 
Table 2. ​Project Materials and Total Costs 
Item Count Cost ($) 
HEK293 Cell Line 1 400 
RD114 Viral Vectors 2 400 
GFP and RFP Constructs 1 500 
Cell Culture Media 1 400 
Cloning Kit 1 200 
E. coli​ Cells 1 250 
Puromycin 1 500 
Tissue Culture Materials 1 500 
Total  3,000 
 
The most important aspect of this project is the HEK293 cell lines. Along with this, the cell 
culture media is necessary to provide nutrients for our cells and keep them alive in a stable 
environment. Finally, the RD114 viral vectors with the GFP and RFP are essential elements to 
target exosomes and visualize their location throughout the cell.  
 
1.7.3 Project Timeline 
During fall quarter, we became comfortable in the laboratory by learning effective protocols and 
proper techniques. With the time we had over winter break we did more research and protocol 
development, paying specific attention to further iterature searches. This allowed us to better 
understand our technology and the role that it plays in targeted drug delivery for HSCs. In the 
winter we began our stable cell line, collected data, and finalized our protocols. This allowed us 
to perform exosome uptake experiments and prepare for our conference presentation throughout 
the beginning of spring quarter. Finally, we finished compiling and analyzing our results during 
the end of spring quarter to develop this draft of our final thesis.  
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Chapter 2: Development of Stable Cell Line 
 
2.1 Introduction 
We began with human embryonic kidney (HEK) cells. More specifically, our project utilized 
HEK293 cells, which come from a permanently modified cell line that is particularly amenable 
to the introduction and expression of new genes.  Historically, these cells have been manipulated 
to produce recombinant proteins derived from the genes of both mammalian and non-mammalian 
organisms. We found this particular cell line to be relevant for our project because it contains 
sophisticated biochemical machinery that can execute essential post-translational modifications 
(17). 
 
Simple transfection protocols represent just one of the ways in which these cells can be 
genetically modified for engineered protein production. We used this method to introduce a 
foreign construct into our HEK293 cells. This construct contained four critical domains that were 
essential to either the validation of our transformed cell line or to the final application of the 
engineered exosomes. These domains are as follows: 
 
1. A luminescent reporter gene that could provide sensitive, quantitative information 
concerning the extent to which our construct was expressed. 
2. A fluorescent reporter gene that could provide a quick, qualitative indication of 
fluorescence while also showing where the expressed proteins from our construct were 
localized in the cells. 
3. A puromycin resistance reporter gene that could allow us to impose a selective pressure 
on the cell line based on the successful integration of our specific construct. 
4. A gene encoding for the RD114 protein, which would become integrated in the exosome 
membranes to allow for specific binding of those nanoparticles to the surface antigens of 
hematopoietic stem cells. 
 
We transfected our cells using our designed construct and polyethyleneimine, which enhances 
transfection efficiency by allowing the construct to avoid acidic lysosomal degradation as it is 
transported to the nucleus of the cell (18). Though transfection protocols are relatively easy to 
execute, they demand a certain amount of time before we can confirm that our introduced DNA 
has been effectively integrated into the actual genome of the cell line. 
 
We ultimately allowed our cells to grow in puromycin culture for over 40 days. As a result of 
this stage in the cell culturing process, any cells that did not integrate the construct into their 
genomes would be killed after the many stages of cell division that would dilute the presence of 
our construct in the cells where no complete integration had occurred. Meanwhile, other cells 
integrated this DNA into their chromosomes. This integration allowed for successful replication 
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and transcription of our construct. Following this transcriptional process, the newly formed 
mRNA would then be translated into the proteins corresponding to the four domains of our 
construct. These cells would then finally be assessed for their ability to produce exosomes tagged 
with our proteins of interest, but that will be discussed in the next chapter. 
 
2.2 Key Constraints 
When approaching the process of creating a stable cell line, there are some key constraints that 
must be taken into consideration. The first set of constraints are with the HEK293 cells. The 
limitations around these cells include the conditions that the cells must be cultured in and the 
risks of contamination. The cells need to be kept in the proper conditions to grow and avoid cross 
contamination between plates. To avoid other contamination from outside sources, proper 
protective equipment is used. Gloves and lab coats are necessary while in contact with the 
culture plates and ethanol is used when moving the plates from one sterile location to another to 
prevent an outside contaminant. The second set of constraints are related to the issue of time. 
One time limitation is simply how fast the cells can grow. If the cells are not confluent enough, it 
could delay some of our experiments until enough cells are present. Another issue is that once 
the cells have been transfected with the gene, the cells must continue to produce exosomes with 
the target protein present for at least 40 days to become a stable cell line. If a problem comes up 
during this process, there may not be time to start the process over. 
 
2.3 Design Approach 
Our design approach to create the stable cell lines began with the vector construct. Our vector 
contains genes that produce a protein that goes to the surface of exosomes and targets HSCs. 
Specifically, our vector includes an RD114A gene that goes to the outside of the exosome 
surface once translated into a protein and promotes the uptake of these exosomes by HSCs. Next, 
the puromycin resistance gene and polyA tail provide selective resistance for our cells and 
stability for the protein respectively. And finally, the gluc and GFP/RFP act as reporter genes for 
our exosomes so we can quantify our protein production and visualize protein movement in the 
cells. These portions of the protein are inside the exosomes. As explained above, these genes are 
both inserted into our HEK293 cells using transfection and selected for with puromycin pressure. 
The cells that have taken up our gene will have a puromycin resistance so they can live in the 
puromycin media while the rest of the cells die under this pressure. This will allow us to culture 
the cells for 40 days to create a stable cell line containing the desired genes.  
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Figure 1.​ Vector constructs used for cell line transfection. 
 
 
Figure 2.​ Schematic of protein complexes expressed within the membranes of engineered 
exosomes produced by the two stable cell lines. 
 
2.4 Supporting Analyses 
This stage of our experiment gave rise to a stable cell line that seemed to successfully express 
our construct throughout the cell culture. We observed relatively high levels of fluorescence 
under a fluorescent microscope immediately following the transfection. After 40 days of growth 
in puromycin media, fluorescence decreased, but was still present. This suggests that, even 
though expression of our gene seemed to decrease over time, our construct was still visibly 
present in the cell line. 
 
2.5 Expected Results 
To create our stable cell line, our cells must survive for 40 days under pressure and continue to 
produce our desired protein. To prove that this has happened, we cultured our cells with 
puromycin expected only the cells containing our vector construct to survive. We could then 
support this evidence with microscope imaging of the GFP and RFP proteins in the cells. If our 
cells were still producing our protein, we would expect to see either green or red fluorescence 
present in the cells.  
 
2.6 Backup Plan 
Should transfection methods not have been successful in generating a stable cell line that 
expressed our desired proteins, we could then have turned to transduction methods. These 
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methods would allow us to obtain a verified stable cell line in less time, but they would 
ultimately require additional steps to successfully package a lentivirus gene delivery system for 
our HEK293 cell line.  
 
2.7 Materials and Methods 
2.7.1 Cell Culture Passaging 
Materials: 
● 70% Ethanol 
● Light-Duty Tissue Wiper 
● 1000𝜇L pipette 
● Aspirator  
● Pipette Controller 
● Aspirating tips 
● 5mL Pipette tips 
● 2mL Pipette tips 
● Dulbecco’s Modified Eagle’s Medium (DMEM) 
● Trypsin 
● Phosphate Buffered Saline (PBS) 
● 100x20 mm cell culture plate 
 
Methods: 
1. Take cell culture plates out of the 37°C incubator and check the confluency of the cell 
under the microscope. If the confluency is 70% or above, the cell culture can be 
passaged. 
2. Collect DMEM, PBS, and trypsin tubes from stock and place them in the 37°C water 
bath. 
3. Prepare the hood by spraying down the surface with 70% ethanol and wiping it with a 
light-duty tissue wiper.  
4. Collect and spray the following equipment with 70% ethanol and place inside the hood: 
a. 1000𝜇L pipette 
b. Aspirator  
c. Pipette Controller 
d. 3 Aspirating tips 
e. 3 5mL Pipette tips 
f. 1 2mL Pipette tips 
g. DMEM 
h. Trypsin 
i. PBS 
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5. Attach an aspirating tip to the aspirator and aspirate off the DMEM while the plate is 
tilted at a 45 degree angle minimizing the cell exposure.  
6. Add 3mL of PBS to the wall of the plate at a 45 degree angle. Set the plate down. 
7. Repeat aspirating technique to remove PBS. 
8. Add 1.5mL of trypsin to the plate and place in the incubator for 2 minutes. 
9. Remove plate from the incubator and add 5mL of DMEM to the plate in the hood.  
10. Collect all the liquid with the suspended cells from the plate using the pipette tip and put 
it in a 15mL tube.  
11. Centrifuge the 15mL tube with the cell suspension at 1500rpm for 5 minutes.  
12. Back in the hood, aspirate off the supernatant. 
13. Add 7mL of DMEM to a clean 100x20mm cell culture plate and resuspend the cells in 
the 15mL tube in 4mL of DMEM. 
14. Add 250𝜇L of resuspended cells to the clean cell culture plate. 
15. Check cell culture plate for the presence of suspended cells. If cells are present, place cell 
plate in the incubator to grow.  
 
2.7.2 Mammalian Cell Transfection 
Materials: 
● Micropipettes 
● 6-well plate 
● 1.5 mL microcentrifuge tubes 
● Plasmid 
● Dulbecco’s Modified Eagle’s Medium (DMEM) 
● PEI transfection reagent 
● Opti-MEM + 1% PBS 
 
Methods: 
1. Pipette 2 mL of DMEM into each well of a 6 well plate. 
2. Transfer 45 𝜇L of the final passaging suspension from the original HEK293 cell culture 
to each well of the plate. 
3. For each well that is to be transfected, obtain two microcentrifuge tubes. Add 100 𝜇L of 
Opti-MEM + 1% PBS to both tubes.  
4. Then add 10 𝜇L of PEI reagent to one tube and 2 𝜇g of plasmid to the other tube. Use the 
pipette to mix both solutions. 
5. Finally, transfer the contents of the tube containing Opti-MEM + 1% PBS and PEI 
reagent to the other tube. Mix the contents of this tube together and wait for 20 minutes 
before proceeding to the next step. 
6. Add 220 𝜇L of the mixture in the tube to the well that is to be transfected with that 
plasmid. 
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7. Place the plate in the incubator and allow the cells to grow for two days before 
performing other experiments with these transfected cells.  
 
 
2.8 Results 
To verify that our stable cell lines contained our desired genes and produced the proteins of 
interest, green and red fluorescent images were taken of the cells after 40 days in puromycin. A 
confocal microscope was used to take fluorescent and phase images of both cell lines. 
Photograph editing software was then used to overlay these images. The images from these tests 
are shown in Figure 3. 
 
 
Figure 3.​ Fluorescent and phase confocal microscopy images of the stable cell lines. 
 
These images indicate that the cells survived in puromycin after 40 days. The white arrows in the 
fluorescent and overlay images indicate the presence of GFP and RFP in the cells.  
 
2.9 Discussion 
The results seen in Figure 3 show that the cells survived in the puromycin media after 40 days, 
demonstrating that the puromycin resistance gene is present in the cells. The images also show 
green and red fluorescence dots inside the living cells, proving that the GFP and RFP genes are 
being translated in the cells. These results show that the puromycin resistance gene and 
fluorescent protein genes are both present in the cell genome and continue to be translated by the 
cell. Ultimately, this indicates that the cell lines are stable.  
  
18 
Chapter 3: Hematopoietic Stem Cell Targeted Exosome Production 
 
3.1 Introduction 
Following the transfection of our cells with our construct, we turned our attention to exosome 
analysis so that we could validate whether our HEK293 cell line could produce exosomes with 
the relevant proteins of interest. Exosomes are produced through a sequence of endocytosis, 
invagination, and exocytosis (​19). The outer membrane of the cells first creates pockets leading 
into the cytoplasm of the cell. The surface of the cell membrane then joins together to produce a 
small vesicle within the interior of the cell. This vesicle is called an endosome. 
 
Once inside the cell, a similar process occurs in the membrane of the endosome. Even smaller 
pockets form within its membrane that eventually give rise to smaller vesicles within the larger 
endosome. The ultimate product of this invagination stage is a multivesicular body with a 
collection of naturally produced nanoparticles contained within the larger carrier. These 
nanoparticles contain material from the interior of the cell, which is critical to the final purpose 
of exosomes both in the natural world and in its engineering applications. 
 
Finally, the endosome fuses with the exterior membrane of the cell to release the contained 
exosomes to the extracellular environment. These nanoparticles then have the opportunity to fuse 
to the outer membranes of other cells to deliver their cargo. 
 
3.2 Key Constraints 
The main constraints of targeted exosome production lies in the actual harvesting of these 
nanoparticles. The exosomes must be produced by HEK293 cells that contain the target gene in 
order for them to be tagged with the desired protein. This means that the cells must be 
transfected or the stable cell line must be established before the exosomes can be harvested. 
Additionally, harvesting a pure, concentrated sample of exosomes can be difficult due to other 
small particles and the cell culture’s inherent level of exosome production.  
 
3.3 Design Approach 
For this step of the project, our goal was to collect and isolate exosomes from our stable cell line 
to test them for exosomal qualities and the presence of our proteins. To do this, we harvested the 
exosomes from the media of transient and stable cell line plates, centrifuged them, and 
resuspended them at a relatively high concentrations. This allowed us to check the properties of 
the particles to confirm that they were the desired, engineered exosomes.  
 
3.4 Supporting Analyses 
This stage of our project provided us with evidence of the successful production of exosomes 
from our stable cell line that were tagged with the our proteins of interest. The produced and 
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isolated exosomes were of the correct size, contained surface markers that are characteristic of 
HEK293 cell exosomes, exhibited luciferase activity, and demonstrated fluorescence in the 
cytoplasms of the cells. 
 
3.5 Expected Results 
In this series of experiments, there were several ways in which we intended to analyze our 
harvested exosomes. The first method used was a Nanoparticle Tracking Analysis (NTA) test. 
This indicated the size of the particles present in our exosome sample. We expected to see a 
significant peak at 30-100 nm and no other peaks on the graph. Next, we conducted an 
enzyme-linked immunosorbent assay (ELISA), which provided insight into the surface proteins 
on the nanoparticles. We expected to see evidence that the CD63 surface antigen was present on 
the surfaces of these nanoparticles. After proving that our nanoparticles were exosomes, we 
analyzed for the presence of the engineered proteins in the exosomes. To do this, we used 
confocal microscope imaging to visualize the living cells in puromycin media and analyzed for 
the localization of the fluorescent reporter genes in the cells. We also performed a luciferase 
assay to determine whether our luciferase gene was integrated into the cell and expressed within 
the exosomes.  
 
3.6 Backup Plan 
Our goal was to collect results using exosomes from our stable cell line; however, if our cell line 
was not yet stable, we could also harvest exosomes by transfecting a new HEK293 cell line with 
our gene and collecting the exosomes produced by these cells at their transient phase of 
expression.  
 
3.7 Materials and Methods 
3.7.1 Exosome Harvest 
Materials: 
● 145x20 mm cell culture plate 
● 15 mL tubes 
● Pipette controller 
● Micropipettes 
● DMEM 
● Plasmid 
● Dulbecco’s Modified Eagle’s Medium (DMEM) 
● PEI transfection reagent 
● Opti-MEM + 1% PBS 
● UltraCULTURE + 1% P/S Glut 
● 30 mL syringe 
● Sterile syringe filter with 0.2 𝜇m polyethersulfone membrane 
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● Exo-TC exosome precipitation solution 
● Phosphate-buffered saline (PBS) 
 
Methods: 
Day One 
1. Complete a passage of a cell culture. 
2. Pipette 20 mL of DMEM to the 145x20 mm cell culture plate. 
3. Add about 2 mL of the final passaging suspension to the the plate. 
4. Place the plate in the incubator. 
Day Two 
1. If the cell line has already been transfected with the plasmid of interest, allow the cells to 
grow on this day. 
2. If the cell line must be transfected, obtain two 15 mL tubes. Add 1 mL of Opti-MEM + 
1% PBS to both tubes.  
3. Then add 100 𝜇L of PEI reagent to one tube and 20 𝜇g of plasmid to the other tube. Use 
the pipette to mix both solutions. 
4. Finally, transfer the contents of the tube containing Opti-MEM + 1% PBS and PEI 
reagent to the other tube. Mix the contents of this tube together and wait for 20 minutes 
before proceeding to the next step. 
5. Add 2 mL of the mixture in the tube to the plate. 
6. Place the plate in the incubator. 
Day Three 
1. Take cell culture plates out of the incubator and place in clean hood. 
2. Aspirate off the existing DMEM by tilting the plate at a 45 degree angle away to 
minimize cell exposure.  
3. Add 20mL of UltraCULTURE + 1% P/S Glut to the cell culture plate and place back in 
the incubator 
Day Four 
1. Allow cells to grow. 
Day Five 
1. Transfer all media from the plate to a 50 mL tube and spin the tube in the centrifuge at 
1,500 g’s for 10 minutes. 
2. Obtain a new 50 mL tube and open the 30 mL syringe. 
3. Screw the sterile syringe filter with the 0.2 𝜇m polyethersulfone membrane onto the 
barrel of the syringe. Fit the syringe filter and barrel into the top of the 50 mL tube. Pull 
the plunger out of the syringe barrel. 
4. Next, transfer the media from the tube that was spun in the centrifuge to the barrel of the 
syringe. 
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5. Using the plunger of the syringe, push the media through the filter of the syringe and into 
the 50 mL tube to filter out the cell debris. 
6. Add 5 mL of Exo-TC to the 50 mL tube and invert the tube a few times to ensure proper 
mixing. 
7. Place the tube in the refrigerator overnight. 
Day Six 
1. Spin the 50 mL tube in the centrifuge at 3,000 g’s for one hour and 30 minutes. 
2. Pour off the media into the sink and add 150 𝜇L of specific PBS to the tube, mixing the 
solution in the tube to effectively resuspend the pellet. 
 
3.7.2 Exosomal Luciferase Assay 
Materials: 
● Exosome Samples 
● Luciferase Substrate 
● 96-well plate 
● 200𝜇L pipette 
● Plate reader 
 
Methods: 
1. Collect exosome samples from exosome harvest, luciferase substrate, 96-well plate, and 
200𝜇L pipette. 
2. Vortex the exosome samples thoroughly. 
3. Add 20𝜇L of each sample to three wells skipping a column of wells between samples to 
minimize interference from neighboring samples.  
4. Add 100𝜇L of luciferase substrate to the sample wells and place well plate into the plate 
reader. 
5. Run luciferase assay program on the computer and save results. 
 
3.7.3 Enzyme-Linked Immunosorbent Assay 
Materials: 
● ExoELISA-ULTRA protein 
● Coating Buffer 
● Microcentrifuge tubes 
● Vortexer 
● 96-well Plate 
● Micropipettes 
● Blocking Buffer 
● Super-sensitive TMB ELISA substrate 
● Stop buffer 
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● Plate reader 
● Wash Buffer 
 
Methods: 
Creating Exosome Protein Standard Curve 
1. Thaw ExoELISA-ULTRA protein standard on ice. 
2. In a microcentrifuge tube, create a 1:1000 dilution by add 1𝜇L of protein standard to 1mL 
of coating buffer and vortex to mix the solution. 
3. Using this first dilution, perform serial dilutions 6 more times using 60𝜇L of the previous 
dilution and 60𝜇L of coating buffer. Vortex each dilution.  
ExoELISA Assay 
1. In a 96-well plate, add 50𝜇L of prepared protein standards and 50𝜇L of exosome samples 
to the wells. 
2. Cover the plate with film(or cover) and incubate the plate for 1 hour at 37°C. 
3. After incubation, remove the liquid and wash the plate 3 times for 5 minutes using 100𝜇L 
of 1x Wash Buffer. 
4. To prepare the CD63 primary antibody, dilute it using a 1:100 dilution in Blocking 
Buffer. 
5. Add 50𝜇L of the primary antibody dilution to each well and incubate at room temperature 
for 1 hour with shaking. 
6. After incubation, was the plate 3 times for 5 minutes using 100𝜇L of 1x Wash Buffer.  
7. To prepare the secondary antibody, dilute it using a 1:5,000 dilution in Blocking Buffer. 
8. Add 50𝜇L of the secondary antibody dilution to each well and incubate at room 
temperature for 1 hour with shaking. 
9. After incubation, was the plate 3 times for 5 minutes using 100𝜇L of 1x Wash Buffer.  
10. Add 50𝜇L of room temperature Super-sensitive TMB ELISA substrate to each well and 
incubate at room temperature for 15 minutes with shaking.  
11. Add 50𝜇L of Stop buffer to each well and read with a spectrophotometric plate reader at 
450 nm immediately to provide a fixed endpoint for the assay. 
 
3.8 Results 
After creating the stable cell lines, the nanoparticles produced were analysed to determine if they 
were exosomes and if the desired protein was present on these exosomes. The first test was a 
Hoechst stain of both cell lines. This allowed us to visualize where the GFP and RFP were 
present within the cells. Next, luciferase assays were run on the exosomes harvested from the 
transient cell lines and on the exosomes harvested from the stable cell lines, after 40 days had 
passed in puromycin media. This provided results on the presence of the gLuc gene in the cell 
lines. Finally, the nanoparticles were analyzed with NTA and ELISA tests to further characterize 
their properties. 
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Figure 4.​ Fluorescent, phase, and nuclear stain confocal microscope images of the stable cell 
lines.  
 
Figure 4 illustrates the localization of the exosome by staining the nucleus of the cells and 
overlaying these images with fluorescent and phase images of the cells. This indicates the 
location of the proteins in comparison to the nucleus of the cell.  
 
 
Figure 5.​ Luciferase analysis of exosomes harvested from the transient cell lines. 
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Figure 6.​ Luciferase analysis of exosomes harvested from the stable cell lines.  
 
The luciferase assays for both the transient cell lines and the stable cell lines show a significantly 
higher expression of the gLuc gene than the control. This is known because the p-values for all 
four samples, relative to the control, are well below 0.05 which indicates a significant difference 
from the control.  
 
 
Figure 7.​ Nanoparticle Tracking Analysis (NTA) of exosomes harvested from the GFP and RFP 
cell lines.  
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The mean diameter of exosomes from the GFP cell line was 62.6 nm, with a standard deviation 
of 1.1 nm. The mean diameter of the exosomes from the RFP cell line was 62.1 nm, with a 
standard deviation of 3.2 nm. Three trial runs were conducted for each sample. The expected 
range of exosome diameters is between 30 nm and 100 nm and both of these samples fall well 
within this range. Additionally, both samples produced a single, sharp peak. This ultimately 
indicates that the exosomes isolated from these cell lines were relatively pure. 
 
 
 
Figure 8.​ ELISA results for exosomes harvested from both the GFP and RFP transient cell lines. 
 
3.9 Discussion 
These analytical approaches demonstrate that the exosomes produced from our stable cell lines 
exhibit the expected properties. The Hoechst stain, when viewed under the confocal microscope, 
reveals that the engineered proteins are located in the cytosols of the cell line. This confirms that, 
at a minimum, the fluorescent reporter gene of our construct was successfully expressed. The 
luciferase assays were conducted with the isolated exosomes from both the transient and stable 
cell lines. In both assays, significantly higher luciferase activity was observed in the GFP and 
RFP stable cell lines’ exosomes relative to a control. This finding indicates that the protein 
corresponding to the inserted construct was, in fact, present in the exosomes. Luciferase 
expression was, however, lower in the stable cell lines’ exosomes than it was in the transient cell 
lines’ exosomes. This drop in luciferase expression suggests that the expression of the construct 
decreased over time. Such a result may be due to the CMV promoter that was included in our 
construct. This promoter may allow for high levels of protein expression soon after transfection, 
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but it may not be capable of providing those levels of protein expression for a sustained period of 
time.  
 
Further tests were conducted to characterize these isolated exosomes. The Nanoparticle Tracking 
Analysis revealed that these exosomes were of the expected size. The results show a peak 
ranging from 30 to 100 nm, which corresponds to the known size of these nanoparticles. 
Additionally, these results showed that the sample was pure, as one clearly defined peak was 
generated from this test. The ELISA assay was used to screen for the presence of CD63, a 
protein common to exosomes. The obtained graph shows that this protein was present in the 
obtained sample, indicating that the isolated nanoparticles were, in fact, exosomes. 
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Chapter 4: Tagged Exosome Uptake by Hematopoietic Stem Cells 
 
4.1 Introduction 
After isolating the exosomes from our cell lines and characterizing them according to the 
properties discussed in previous chapters, the next critical step was to assess these exosomes for 
their ability to undergo uptake into other living cells. For the scope of this project, a test was only 
conducted to see if these nanoparticles were capable of entering an unmodified HEK293 cell 
line. Upon incubating this cell line with the isolated exosome from the transfected cell lines, the 
locations of the exosomes could be monitored simply by confocal microscopy, where exosome 
uptake was confirmed through the fluorescence of the cultured cells. This provided basic insight 
into the therapeutic potential of these nanoparticles and suggested future directions that may be 
of interest as this project moves forward. 
 
4.2 Key Constraints 
The ideal uptake experiment would include the cell line that this system is intended to target. 
Unfortunately, for a variety of reasons, HSCs are relatively difficult to procure for these tests. If 
the exosomes are only exposed to a single cell line, they will ultimately enter those cells over 
time. After all, the exosomes are comprised of a phospholipid bilayer that is sourced from living 
cells, thus allowing for their surfaces to fuse. This constraint limits the conclusions that we are 
able to draw from these findings and leads us to consider future steps that might address these 
remaining questions. 
 
4.3 Design Approach 
The design approach to conduct uptake experiments relies heavily on our harvested exosomes 
from the stable cell lines. We were able to plate HEK293 cells with the exosomes from the GFP 
and RFP cell lines to determine if the exosomes would enter the cells over time.  
 
4.4 Supporting Analyses 
This stage of the experiment revealed the proclivity of these engineered nanoparticles to enter 
another cell line. Though no selectivity could be observed, the exosomes were capable of 
entering the cells that they were cultured with over 72 hours. This may generate questions 
concerning the selective capabilities of these nanoparticles once they enter a living system. 
Future ​in vivo​ testing would need to be designed in such a way that would allow for the explicit 
observation of exosome uptake into targeted cells (HSCs, in this case) over healthy tissues. This 
basic property is, after all, paramount to the purpose of this project. 
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4.5 Expected Results 
For these experiments, the uptake of the exosomes by the HEK293 cells was verified by imaging 
the cells with a confocal microscope. This showed if the exosomes were inside the cells or not. 
For these experiments, the exosomes were expected to be seen inside the cells. 
 
4.6 Backup Plan 
The backup plan for the uptake experiments was to introduce the exosomes to another cell line. 
Although we could not acquire HSCs to do our uptake, we had access to a U87 cell line that we 
could conduct these experiments on. The U87 cell line is a human glioblastoma cell line that 
would have similar results to the HEK293 cell line when used for an uptake experiment.  
 
4.7 Materials and Methods 
4.7.1 Uptake Experiment  
Materials: 
● Harvested Exosomes 
● Micropipettes 
● Four quadrant glass bottom confocal plate 
● 1.5 mL microcentrifuge tubes 
● UltraCULTURE + 1% P/S Glut 
 
Methods: 
1. Plate HEK293 cell line in three quadrants of four quadrant glass bottom confocal plate.  
2. Dilute GFP, RFP, and control harvested exosomes to a concentration 0.3𝜇g/𝜇L using 
UltraCULTURE to make 200𝜇L of solution.  
3. Plate each of the the 200𝜇L of dilutions of exosomes onto one of the three quadrants of 
the HEK293 plate. 
4. Image the cells at 24, 48, and 72 hours with the confocal microscope to observe the 
uptake of the exosomes.  
 
4.8 Results 
In the uptake experiments, images are taken with the confocal microscope at 24, 48, and 72 
hours in order to visualize the exosomes presence in the cells. These images are taken of the GFP 
and RFP harvested exosomes against control exosomes.  
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Figure 9.​ Confocal images of exosomes harvested from the GFP and control cell lines plated 
with HEK293 cells. Images were taken after 24, 48, and 72 hours. 
 
 
Figure 10.​ Confocal images of exosomes harvested from the RFP and control cell lines plated 
with HEK293 cells. Images were taken after 24, 48, and 72 hours. 
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These images show that the GFP and RFP exosomes did enter the cells within 24 hours and they 
continued to enter the cells throughout the 72 hour period.  
 
4.9 Discussion  
The findings of these experiments provide assurance that these engineered exosomes can enter 
living cells and be visualized upon uptake. This ultimately indicates that future experiments can 
be successfully conducted upon the acquirement of proper cell lines. Observing the capability of 
these exosomes to enter a living system provides a proof of concept that illustrates the basic 
functionality of these nanoparticles. With that in mind, though, more tests must be conducted to 
determine whether these nanoparticles can selectively enter HSCs over other cell lines. Once 
those tests are conducted, further engineering must be conducted to successfully load these 
nanoparticle with therapeutic cargo.  
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Chapter 5: Conclusion 
5.1 Conclusions and Summary 
The goal of this project was to develop a stable cell line that was capable of producing targeted 
exosomes carrying the protein complex of our engineered construct. Through the analysis of the 
cell lines and their corresponding isolated exosomes, we were able to show that the transfected 
cell lines produced modified living nanoparticles. These nanoparticles exhibited the expected 
properties that are universal to exosomes and the characteristics associated with the reporter 
genes that were included in our initial construct. All of these findings collectively indicate that 
the exosomes produced from these cell lines carry the proteins corresponding to the inserted 
genes. Additionally, the harvested exosomes from these cell lines are capable of entering live 
cells. More work must be done, however, to explore the capability of these exosomes to 
selectively enter the HSC target cell over other cell types.  
 
5.2 Future Steps 
5.2.1 Experimental Uptake with Other Cell Lines 
During this project, we were able to create a stable cell line that produced modified exosomes 
and test them with uptake experiments using a HEK293 cell line. The next step in this project 
would be to test these modified exosomes on other cell lines, including HSCs, to confirm that 
they can deliver their proteins to different cell lines. Once this is shown to work for multiple cell 
types, the exosomes should be introduced to HSCs with another cell line present to see if they 
selectively enter HSCs over other cell types. To prove this, the engineered exosomes would need 
to be introduced to plates with both HSCs and another cell line present and then similar 
observations would be made over 72 hours. In these 72 hours, we would expect the exosomes to 
preferentially enter the HSCs so the HSCs would have significantly more exosomes inside of 
them over the other cell line. This would show that the exosomes specifically target HSCs and 
could potentially be used to deliver drugs to these cells over other cell types in the body. 
 
5.2.2 Personalized Treatment  
A step that can be studied more in the future is around personalizing the patient’s treatment. Our 
engineered exosomes have shown that they can enter a HEK293 cell line, but there is still plenty 
of research to be done before they can be used to deliver therapeutics to HSCs in a patient. One 
potential treatment option for consideration is the creation of a delivery system specific for the 
patient. One way this could be done is by using the own patient’s HSCs to produce the exosomes 
that will be administered to them. The patient’s HSCs would have to be extracted and cultured 
similarly to the HEK293 cells for this project. Once the HSCs have been cultured, the therapeutic 
DNA would be inserted into the genome and the HCSs would start producing modified 
exosomes. Since these exosomes would be created using the patient’s own cells, there would be 
no question of exosome compatibility for the patient and therefore it be a safer treatment option. 
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Chapter 6: Engineering Standards 
6.1 Manufacturability Concerns 
This project’s focus of creating a stable cell line that can produce targeted exosome is directly 
related to manufacturing of our product. Once a stable cell line is established, it will be able to 
continue to make exosomes with the targeted therapeutic attached to them. HEK293 cells are 
fairly resilient cells and would be relatively cheap to maintain with the use of larger bioreactors 
and a system for extracting exosomes. This gives our project the potential to be manufacturable 
in the future.  
 
6.2 Ethical Concerns 
The main ethical issues around this project is the human embryonic kidney cells we are working 
with. Although the cell line is a clone of cells taken from a legally aborted fetus, it still raises a 
lot of questions about the implications of experimenting on human cells. There is a concern that 
because the cells are from a fetus, there was no consent and that the use of them devalues human 
life. Not only does this affect the researchers working with the cells, but it can also affect the 
people using the product. These are topics that we must consider when using human embryonic 
cells.  
 
6.3 Health and Safety Concerns 
Health and safety concerns are important to address when creating a new product because they 
can be an issue for both the researcher and the consumer. For the researcher, it is important that 
proper safety precautions are taken to avoid harm. This includes wearing clothing that protects 
your skin such as gloves, lab coats, long pants and closed toe shoes. It is also necessary to use 
biosafety hoods with ventilation and ethanol between sterile locations for the researcher safety 
and to limit the opportunity for contamination of the cells. As for the concerns of the consumer, 
this project with a focus on targeted drug delivery, could help eliminate long and painful 
treatments with extensive side effects. It would allow a therapeutic to be delivered directly to the 
cells of interest and improve the health of the patient.  
 
6.4 Environmental Concerns 
Increasing use of nanoparticle technology has encouraged research regarding the potential 
environmental impact of such materials. Unfortunately, questions surrounding these topics 
remain largely unanswered. Nanoparticle environmental impact is ultimately governed by the 
collective effects of their various properties, including their chemical composition, size, and 
structure. Other nanoparticles have been engineered from compounds that are actually toxic to 
living organisms when they reach critical physiological levels (López-Serrano). Therefore, many 
studies must be conducted to understand bioaccumulation of nanoparticles within the 
environment. Exosomes, however, overcome this potential concern. Because they are naturally 
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produced, the body is capable of degrading these nanoparticles, thus preventing harmful 
accumulation of toxic material in the environment. 
 
Additionally, the manufacturing process outlined in this project is relatively free of 
environmentally hazardous materials. Any hazardous materials that were produced through these 
procedures, however, was properly disposed of by the SCU Department of Bioengineering. 
 
6.5 Political Concerns 
The ethical concerns of this specific exosome application may be of greater concern in later 
stages of development when this technology may be considered for use in other countries across 
the globe. Policies will obviously vary greatly from those of the United States. Perhaps the 
utilization of human embryonic kidney cells could be perceived as ethically problematic and 
even prevent this technology from being adopted. The simple fact of the matter is that all large 
populations will likely include patients suffering from defective hematopoietic stem cell 
function, regardless of geography. Should the ethical concerns become an insurmountable 
barrier, however, then perhaps it will become necessary to successfully replicate this technology 
in a different cell line that does not elicit as many ethical concerns.  
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